Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112583 - PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS

Publication Number WO/2020/112583
Publication Date 04.06.2020
International Application No. PCT/US2019/062905
International Filing Date 25.11.2019
IPC
C07D 413/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 413/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
C07D 417/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 417/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14containing three or more hetero rings
C07D 498/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61P 9/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
CPC
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 9/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07D 413/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 413/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
C07D 417/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Applicants
  • BRISTOL-MYERS SQUIBB COMPANY [US]/[US]
Inventors
  • WURTZ, Nicholas, R.
  • JOHNSON, James, A.
  • PI, Zulan
  • VIET, Andrew, Quoc
Agents
  • LIU, Hong
  • GREENBLATT, Gary D.
  • BARBIC, Andrej
  • BELLOMY, Gregory R.
  • CHAO, Yuan
  • CLAUSS, Isabelle M.
  • COULTER, Kathryn
  • DELAUNEY, Ashton J.
  • FARQUHARSON-TORRES, Serena
  • GOLIAN, Paul D.
  • GUO, Z. Angela
  • HADAD, Henry
  • HAI, Bing
  • HAN, Bo
  • JACOBSEN, Barry H.
  • KORSEN, Elliott
  • LAUB, Friedrich Bernhard
  • SUN, Jing G.
  • VANATTEN, Mary K.
  • VOM WEGE, Julia
  • WALSH, Brian J.
Priority Data
62/771,19626.11.2018US
62/819,83218.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS
(FR) DÉRIVÉS DE PYRROLIDINONE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR 2 DU PEPTIDE FORMYLÉ
Abstract
(EN)
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
(FR)
L'invention concerne des composés de formule (I) qui sont des agonistes du récepteur 2 du peptide formylé (FPR2) et/ou des agonistes du récepteur 1 du peptide formylé (FPR1). L'invention concerne également des compositions et des procédés d'utilisation des composés, par exemple pour le traitement de l'athérosclérose, de l'insuffisance cardiaque, et de maladies associées.
Latest bibliographic data on file with the International Bureau